Curation
PascalFrancis
Racine
Curation
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

La maladie de Parkinson en France (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

CONTRIBUTION OF PRE-SYNAPTIC MECHANISMS TO L-DOPA-INDUCED DYSKINESIA

Identifieur interne : 001019 ( PascalFrancis/Curation ); précédent : 001018; suivant : 001020

CONTRIBUTION OF PRE-SYNAPTIC MECHANISMS TO L-DOPA-INDUCED DYSKINESIA

Auteurs : M. Carta [Suède, Italie] ; E. Bezard [France]

Source :

RBID : Pascal:12-0055978

Descripteurs français

English descriptors

Abstract

Positron emission tomography (PET) imaging studies have shown that peak-dose dyskinesia is associated to abnormally high levels of synaptic dopamine (DA) in the caudate-putamen of dyskinetic L-DOPA-treated patients. High striatal extracellular DA levels have also been found in dyskinetic 6-OHDA-lesioned rats as compared to non-dyskinetic ones, suggesting that extracellular DA levels may play a key role in the induction of dyskinesia. In this article we review the evidences pointing to the serotonin system as the primary cause for the abnormally high levels of L-DOPA-derived extracellular DA in Parkinson's disease, and we discuss the feasibility of a therapeutic approach targeting this system.
pA  
A01 01  1    @0 0306-4522
A02 01      @0 NRSCDN
A03   1    @0 Neuroscience
A05       @2 198
A08 01  1  ENG  @1 CONTRIBUTION OF PRE-SYNAPTIC MECHANISMS TO L-DOPA-INDUCED DYSKINESIA
A09 01  1  ENG  @1 Function and Dysfunction of the Basal Ganglia
A11 01  1    @1 CARTA (M.)
A11 02  1    @1 BEZARD (E.)
A12 01  1    @1 BEVAN (Mark D.) @9 ed.
A14 01      @1 Neurobiology Unit, Department of Experimental Medical Science, Lund University, BMC A11, Solvegatan 17 @2 22184 Lund @3 SWE @Z 1 aut.
A14 02      @1 Department of Neuroscience, University of Cagliari, University Campus, SS 554 km 4.5 @2 09042 Monserrato @3 ITA @Z 1 aut.
A14 03      @1 Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293 @2 33000 Bordeaux @3 FRA @Z 2 aut.
A14 04      @1 CNRS, Institut des Maladies Neurodégénératives, UMR 5293 @2 33000 Bordeaux @3 FRA @Z 2 aut.
A15 01      @1 Department of Physiology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Avenue @2 Chicago, IL 60611 @3 USA @Z 1 aut.
A20       @1 245-251
A21       @1 2011
A23 01      @0 ENG
A43 01      @1 INIST @2 17194 @5 354000506028050170
A44       @0 0000 @1 © 2012 INIST-CNRS. All rights reserved.
A45       @0 1 p.3/4
A47 01  1    @0 12-0055978
A60       @1 P
A61       @0 A
A64 01  1    @0 Neuroscience
A66 01      @0 NLD
C01 01    ENG  @0 Positron emission tomography (PET) imaging studies have shown that peak-dose dyskinesia is associated to abnormally high levels of synaptic dopamine (DA) in the caudate-putamen of dyskinetic L-DOPA-treated patients. High striatal extracellular DA levels have also been found in dyskinetic 6-OHDA-lesioned rats as compared to non-dyskinetic ones, suggesting that extracellular DA levels may play a key role in the induction of dyskinesia. In this article we review the evidences pointing to the serotonin system as the primary cause for the abnormally high levels of L-DOPA-derived extracellular DA in Parkinson's disease, and we discuss the feasibility of a therapeutic approach targeting this system.
C02 01  X    @0 002A25
C02 02  X    @0 002B17G
C03 01  X  FRE  @0 Lévodopa @2 NK @2 FR @5 01
C03 01  X  ENG  @0 Levodopa @2 NK @2 FR @5 01
C03 01  X  SPA  @0 Levodopa @2 NK @2 FR @5 01
C03 02  X  FRE  @0 Dopamine @2 NK @2 FR @5 02
C03 02  X  ENG  @0 Dopamine @2 NK @2 FR @5 02
C03 02  X  SPA  @0 Dopamina @2 NK @2 FR @5 02
C03 03  X  FRE  @0 Sérotonine @2 NK @2 FR @5 03
C03 03  X  ENG  @0 Serotonin @2 NK @2 FR @5 03
C03 03  X  SPA  @0 Serotonina @2 NK @2 FR @5 03
C03 04  X  FRE  @0 Maladie de Parkinson @2 NM @5 09
C03 04  X  ENG  @0 Parkinson disease @2 NM @5 09
C03 04  X  SPA  @0 Parkinson enfermedad @2 NM @5 09
C07 01  X  FRE  @0 Antiparkinsonien @5 20
C07 01  X  ENG  @0 Antiparkinson agent @5 20
C07 01  X  SPA  @0 Antiparkinsoniano @5 20
C07 02  X  FRE  @0 Maladie dégénérative @5 21
C07 02  X  ENG  @0 Degenerative disease @5 21
C07 02  X  SPA  @0 Enfermedad degenerativa @5 21
C07 03  X  FRE  @0 Pathologie du système nerveux @5 22
C07 03  X  ENG  @0 Nervous system diseases @5 22
C07 03  X  SPA  @0 Sistema nervioso patología @5 22
C07 04  X  FRE  @0 Pathologie de l'encéphale @5 23
C07 04  X  ENG  @0 Cerebral disorder @5 23
C07 04  X  SPA  @0 Encéfalo patología @5 23
C07 05  X  FRE  @0 Syndrome extrapyramidal @5 24
C07 05  X  ENG  @0 Extrapyramidal syndrome @5 24
C07 05  X  SPA  @0 Extrapiramidal síndrome @5 24
C07 06  X  FRE  @0 Pathologie du système nerveux central @5 25
C07 06  X  ENG  @0 Central nervous system disease @5 25
C07 06  X  SPA  @0 Sistema nervosio central patología @5 25
C07 07  X  FRE  @0 Catécholamine @5 26
C07 07  X  ENG  @0 Catecholamine @5 26
C07 07  X  SPA  @0 Catecolamina @5 26
C07 08  X  FRE  @0 Neurotransmetteur @5 27
C07 08  X  ENG  @0 Neurotransmitter @5 27
C07 08  X  SPA  @0 Neurotransmisor @5 27
N21       @1 037
N44 01      @1 OTO
N82       @1 OTO

Links toward previous steps (curation, corpus...)

Links to Exploration step

Pascal:12-0055978

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">CONTRIBUTION OF PRE-SYNAPTIC MECHANISMS TO L-DOPA-INDUCED DYSKINESIA</title>
<author>
<name sortKey="Carta, M" sort="Carta, M" uniqKey="Carta M" first="M." last="Carta">M. Carta</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Neurobiology Unit, Department of Experimental Medical Science, Lund University, BMC A11, Solvegatan 17</s1>
<s2>22184 Lund</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Neuroscience, University of Cagliari, University Campus, SS 554 km 4.5</s1>
<s2>09042 Monserrato</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author>
<name sortKey="Bezard, E" sort="Bezard, E" uniqKey="Bezard E" first="E." last="Bezard">E. Bezard</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293</s1>
<s2>33000 Bordeaux</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>CNRS, Institut des Maladies Neurodégénératives, UMR 5293</s1>
<s2>33000 Bordeaux</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">12-0055978</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 12-0055978 INIST</idno>
<idno type="RBID">Pascal:12-0055978</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000302</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001019</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">CONTRIBUTION OF PRE-SYNAPTIC MECHANISMS TO L-DOPA-INDUCED DYSKINESIA</title>
<author>
<name sortKey="Carta, M" sort="Carta, M" uniqKey="Carta M" first="M." last="Carta">M. Carta</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Neurobiology Unit, Department of Experimental Medical Science, Lund University, BMC A11, Solvegatan 17</s1>
<s2>22184 Lund</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Neuroscience, University of Cagliari, University Campus, SS 554 km 4.5</s1>
<s2>09042 Monserrato</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author>
<name sortKey="Bezard, E" sort="Bezard, E" uniqKey="Bezard E" first="E." last="Bezard">E. Bezard</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293</s1>
<s2>33000 Bordeaux</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>CNRS, Institut des Maladies Neurodégénératives, UMR 5293</s1>
<s2>33000 Bordeaux</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Neuroscience</title>
<title level="j" type="abbreviated">Neuroscience</title>
<idno type="ISSN">0306-4522</idno>
<imprint>
<date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Neuroscience</title>
<title level="j" type="abbreviated">Neuroscience</title>
<idno type="ISSN">0306-4522</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Dopamine</term>
<term>Levodopa</term>
<term>Parkinson disease</term>
<term>Serotonin</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Lévodopa</term>
<term>Dopamine</term>
<term>Sérotonine</term>
<term>Maladie de Parkinson</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Positron emission tomography (PET) imaging studies have shown that peak-dose dyskinesia is associated to abnormally high levels of synaptic dopamine (DA) in the caudate-putamen of dyskinetic L-DOPA-treated patients. High striatal extracellular DA levels have also been found in dyskinetic 6-OHDA-lesioned rats as compared to non-dyskinetic ones, suggesting that extracellular DA levels may play a key role in the induction of dyskinesia. In this article we review the evidences pointing to the serotonin system as the primary cause for the abnormally high levels of L-DOPA-derived extracellular DA in Parkinson's disease, and we discuss the feasibility of a therapeutic approach targeting this system.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0306-4522</s0>
</fA01>
<fA02 i1="01">
<s0>NRSCDN</s0>
</fA02>
<fA03 i2="1">
<s0>Neuroscience</s0>
</fA03>
<fA05>
<s2>198</s2>
</fA05>
<fA08 i1="01" i2="1" l="ENG">
<s1>CONTRIBUTION OF PRE-SYNAPTIC MECHANISMS TO L-DOPA-INDUCED DYSKINESIA</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG">
<s1>Function and Dysfunction of the Basal Ganglia</s1>
</fA09>
<fA11 i1="01" i2="1">
<s1>CARTA (M.)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>BEZARD (E.)</s1>
</fA11>
<fA12 i1="01" i2="1">
<s1>BEVAN (Mark D.)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01">
<s1>Neurobiology Unit, Department of Experimental Medical Science, Lund University, BMC A11, Solvegatan 17</s1>
<s2>22184 Lund</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Department of Neuroscience, University of Cagliari, University Campus, SS 554 km 4.5</s1>
<s2>09042 Monserrato</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293</s1>
<s2>33000 Bordeaux</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04">
<s1>CNRS, Institut des Maladies Neurodégénératives, UMR 5293</s1>
<s2>33000 Bordeaux</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA15 i1="01">
<s1>Department of Physiology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Avenue</s1>
<s2>Chicago, IL 60611</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA20>
<s1>245-251</s1>
</fA20>
<fA21>
<s1>2011</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>17194</s2>
<s5>354000506028050170</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>1 p.3/4</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>12-0055978</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Neuroscience</s0>
</fA64>
<fA66 i1="01">
<s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Positron emission tomography (PET) imaging studies have shown that peak-dose dyskinesia is associated to abnormally high levels of synaptic dopamine (DA) in the caudate-putamen of dyskinetic L-DOPA-treated patients. High striatal extracellular DA levels have also been found in dyskinetic 6-OHDA-lesioned rats as compared to non-dyskinetic ones, suggesting that extracellular DA levels may play a key role in the induction of dyskinesia. In this article we review the evidences pointing to the serotonin system as the primary cause for the abnormally high levels of L-DOPA-derived extracellular DA in Parkinson's disease, and we discuss the feasibility of a therapeutic approach targeting this system.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002A25</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Sérotonine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Serotonin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Serotonina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>09</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Antiparkinsonien</s0>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Antiparkinson agent</s0>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Antiparkinsoniano</s0>
<s5>20</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>21</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>21</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>21</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Pathologie du système nerveux</s0>
<s5>22</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>22</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>22</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Pathologie de l'encéphale</s0>
<s5>23</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>23</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>23</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Syndrome extrapyramidal</s0>
<s5>24</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>24</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>24</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Pathologie du système nerveux central</s0>
<s5>25</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>25</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>25</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Catécholamine</s0>
<s5>26</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Catecholamine</s0>
<s5>26</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Catecolamina</s0>
<s5>26</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE">
<s0>Neurotransmetteur</s0>
<s5>27</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG">
<s0>Neurotransmitter</s0>
<s5>27</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA">
<s0>Neurotransmisor</s0>
<s5>27</s5>
</fC07>
<fN21>
<s1>037</s1>
</fN21>
<fN44 i1="01">
<s1>OTO</s1>
</fN44>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001019 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001019 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:12-0055978
   |texte=   CONTRIBUTION OF PRE-SYNAPTIC MECHANISMS TO L-DOPA-INDUCED DYSKINESIA
}}
Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024